Dialyzabikity of levofloxacin

Dialyzabikity of levofloxacin - Dialyzabikity of levofloxacin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004867

Enrollment

Registered

2011-01-31

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal failure

Interventions

Four serial blood sampling during single session of hemodialysis. Volume of a blood sampling: 2.5 to 7 ml Total volume of blood: 19ml per patient

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Stable hemodialysis patients with polysulfone dialyzer at Tsukuba Univ. Hospital, Ibaraki or Moka Hosputal, Tochigi Japan. 2) Patients whoe were prescribed levofloxacin due to bronchitis, pneumonia or pyelonephritis. 3) Patients who gaved written informed consent.

Exclusion criteria

Exclusion criteria: 1) Anemia (Hb<9mg/dl) 2) severe hepatic dysfunction (AST 3 times higher than upper normal limit of the insitution. 3)pregnant 4)allergic reaction to levofloxacin 5) history of epilepsy 6) Patients resercher regarded as not suitable

Design outcomes

Primary

Measure	Time frame
determine dialyzer clearance of levofloxacin	—

Secondary

Measure	Time frame
elimination fraction and elimination halflife of levofloxacin	—

Countries

Japan

Contacts

Public ContactShuichi Tsuruoka

Tsukuba University Hospital Nephrology

tsuru@md.tsukuba.ac.jp029-853-3202

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026